Recombinant type-5 vector-based ebola vaccine safe

December 27, 2016

(HealthDay)—For healthy adults from Sierra Leon, the recombinant type-5 vector-based Ebola vaccine is safe and immunogenic, according to a study published online Dec. 21 in The Lancet.

Feng-Cai Zhu, from the Jiangsu Provincial Center for Disease Control and Prevention in Nanjing, China, and colleagues recruited healthy HIV-negative aged 18 to 50 years, with no history of Ebola virus infection and no previous immunization with other Ebola candidate vaccines. Five hundred participants were randomized to receive high-dose (1.6 × 1011 viral particles; 250 participants), low-dose vaccine (8.0 × 1010 viral particles; 125 participants), or (125 participants).

The researchers found that at least one solicited adverse reaction was reported by 53, 48, and 43 percent of in the high-dose, low-dose, and placebo groups, respectively, within seven days of vaccination; most were mild and self-limiting. Vaccine recipients more often had solicited injection-site adverse reactions (26 and 25 percent in the high- and low-dose groups, respectively, versus 17 percent in the placebo group; P = 0.0169). In the low- and high-dose groups, glycoprotein-specific antibody responses were detected from day 14 onward (geometric mean titer, 1,251.0 and 1,728.4, respectively); these peaked at day 28 and decreased rapidly in the following months.

"The recombinant adenovirus type-5 vector-based Ebola vaccine was safe and highly immunogenic in healthy Sierra Leonean adults, and 8.0 × 1010 was the optimal dose," the authors write.

Two authors are employees of Tianjin CanSino Biotechnology, a co-developer of the vaccine.

Explore further: Study examines safety, immune response of candidate Ebola vaccines

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Study examines safety, immune response of candidate Ebola vaccines

April 19, 2016
In a study appearing in the April 19, 2016 issue of JAMA, Matthew D. Snape, F.R.C.P.C.H., M.D., of the University of Oxford, United Kingdom, and colleagues conducted a phase 1 trial to evaluate the tolerability and immunogenicity ...

Two-vaccine Ebola regimen shows promise in early-stage clinical trial

April 19, 2016
An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. Results from the study are described in the April ...

Subunit vaccine efficacious against herpes zoster

April 30, 2015
(HealthDay)—A subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant system (HZ/su) is efficacious against herpes zoster infection in older adults, according to a study published online ...

Experimental zoster vaccine effective in adults aged 70+

September 15, 2016
(HealthDay)—An experimental vaccine against herpes zoster may offer lasting protection for most older adults who receive it, according to a study published in the Sept. 15 issue of the New England Journal of Medicine.

Recommendations updated for meningococcal vaccine in HIV

November 7, 2016
(HealthDay)—In the Nov. 4 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, new recommendations are presented for meningococcal conjugate vaccination among HIV-infected ...

Final trial results confirm Ebola vaccine provides high protection against disease

December 23, 2016
An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to results published today in The Lancet. The vaccine is the first to prevent infection from one of the most ...

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.